The DOI matches its Crossref record; 230 of the 230 references it cites were found in a registry or an index.
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Open accessAbstract
The oral administration of therapeutic peptides and proteins is favoured from a patient and commercial point of view. In order to reach the systemic circulation after oral administration, these drugs have to overcome numerous barriers including the enzymatic, sulfhydryl, mucus and epithelial barrier. The development of oral formulations for therapeutic peptides and proteins is therefore necessary. Among the most promising formulation approaches are lipid-based nanocarriers such as oil-in-water nanoemulsions, self-emulsifying drug delivery systems (SEDDS), solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes and micelles. As the lipophilic character of therapeutic peptides and proteins can be tremendously increased such as by the formation of hydrophobic ion pairs (HIP) with hydrophobic counter ions, they can be incorporated in the lipophilic phase of these carriers. Since gastrointestinal (GI) peptidases as well as sulfhydryl compounds such as glutathione and dietary proteins are too hydrophilic to enter the lipophilic phase of these carriers, the incorporated therapeutic peptide or protein is protected towards enzymatic degradation as well as unintended thiol/disulfide exchange reactions. Stability of lipid-based nanocarriers towards lipases can be provided by the use to excipients that are not or just poorly degraded by these enzymes. Nanocarriers with a size <200 nm and a mucoinert surface such as PEG or zwitterionic surfaces exhibit high mucus permeating properties. Having reached the underlying absorption membrane, lipid-based nanocarriers enable paracellular and lymphatic drug uptake, induce endocytosis and transcytosis or simply fuse with the cell membrane releasing their payload into the systemic circulation. Numerous in vivo studies provide evidence for the potential of these delivery systems. Within this review we provide an overview about the different barriers for oral peptide and protein delivery, highlight the progress made on lipid-based nanocarriers in order to overcome them and discuss strengths and weaknesses of these delivery systems in comparison to other technologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Microemulsion-based media as novel drug delivery systems
Lawrence, M. J., & Rees, G. D. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00103-4 · Cited by 2,040
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
McClements, D. J., & Rao, J. (2011) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.559558 · Cited by 1,630
Nanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358
Solid lipid nanoparticles as a drug delivery system for peptides and proteins☆
ALMEIDA, A., & SOUTO, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.007 · Cited by 814
Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium
Mabbott, N. A., Donaldson, D. S., Ohno, H., Williams, I. R., & Mahajan, A. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.30 · Cited by 721
Preparation, Characterization and Applications of Liposomes: State of the Art
Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C., & Fessi, H. (2012) · Journal of Colloid Science and Biotechnology · doi:10.1166/jcsb.2012.1020 · Cited by 692
Non-invasive delivery strategies for biologics
Anselmo, A. C., Gokarn, Y., & Mitragotri, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 665
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Nanocarrier system: An emerging strategy for bioactive peptide delivery
Zhang, X., Li, X., Zhao, Y., Zheng, Q., Wu, Q., & Yu, Y. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1050647 · Cited by 63
Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review
Cushman, C. J., Ibrahim, A. F., Smith, A. D., Hernandez, E. J., MacKay, B., & Zumwalt, M. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/tknm3388 · Cited by 12
Metadata
- Authors
- Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 182
- Pages
- 114097
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W4206360286
- Cited by
- 424
- References
- 230
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. https://app.cochat.ai/papers/10.1016/j.addr.2021.114097
- The paper
- Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022). Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2021.114097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.